Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Senior Vice President | July 01, 2016 | July 06, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date July 01, 2016 · Filed July 06, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 36,861 |
Ending reported balance
After 2016-07-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2016-07-01 · Grant · Acquired 6,077 · Balance 39,292 F1: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Row 2 · 2016-07-01 · Tax withholding · Disposed 2,431 · Balance 36,861 |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 3,179 |
Reported balance
Holding disclosure · report date 2016-07-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,179 F2: Balance in the Abbott Laboratories Stock Retirement Trust as of July 1, 2016. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy daughter | 2,967 |
Reported balance
Holding disclosure · report date 2016-07-01 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 2,967 F3: The reporting person disclaims beneficial ownership of all securities held by his daughter. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy daughter | 4,433 |
Reported balance
Holding disclosure · report date 2016-07-01 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 4,433 F3: The reporting person disclaims beneficial ownership of all securities held by his daughter. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy son | 4,433 |
Reported balance
Holding disclosure · report date 2016-07-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 4,433 F4: The reporting person disclaims beneficial ownership of all securities held by his son. |
Filing footnotes · ownership attribution and instrument terms
F1: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3.
F2: Balance in the Abbott Laboratories Stock Retirement Trust as of July 1, 2016.
F3: The reporting person disclaims beneficial ownership of all securities held by his daughter.
F4: The reporting person disclaims beneficial ownership of all securities held by his son.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2016 Filed Jul 6, 2016 21:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,431 | $39.31 | $95,562.61 |
DisclosureSEC source: 0001179110-16-027477 · edgar.xml · nonDerivative · entry 2 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,861 Read SEC document |
| July 01, 2016 Filed Jul 6, 2016 21:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 6,077 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-027477 · edgar.xml · nonDerivative · entry 1 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,292 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| June 10, 2016 Filed Jun 17, 2016 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 1,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-026632 · edgar.xml · nonDerivative · entry 5 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 4,433 F3 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his son. Read SEC document |
| June 10, 2016 Filed Jun 17, 2016 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 1,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-026632 · edgar.xml · nonDerivative · entry 4 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 4,433 F2 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his daughter. Read SEC document |
| June 10, 2016 Filed Jun 17, 2016 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 2,934 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-026632 · edgar.xml · nonDerivative · entry 1 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,215 Read SEC document |
| February 29, 2016 Filed Mar 2, 2016 22:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,665 | $39.24 | $65,326.28 |
DisclosureSEC source: 0001179110-16-020664 · edgar.xml · nonDerivative · entry 3 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,149 Read SEC document |
| February 29, 2016 Filed Mar 2, 2016 22:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,280 | $39.52 | $90,105.60 |
DisclosureSEC source: 0001179110-16-020664 · edgar.xml · nonDerivative · entry 2 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,814 Read SEC document |
| February 29, 2016 Filed Mar 2, 2016 22:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 11,394 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-020664 · edgar.xml · nonDerivative · entry 1 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,094 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 22:40 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 194,063 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-16-019888 · edgar.xml · derivative · entry 1 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,063 Underlying: Common shares · 194,063 shares Expires 2026-02-18 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 64,688 on 02/19/2017, 64,687 on 02/19/2018, and 64,688 on 02/19/2019. Read SEC document |
| February 16, 2016 Filed Feb 17, 2016 22:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 233 | $37.13 | $8,651.29 |
DisclosureSEC source: 0001179110-16-019504 · edgar.xml · nonDerivative · entry 2 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,700 Read SEC document |
| February 15, 2016 Filed Feb 17, 2016 22:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 318 | $37.13 | $11,807.34 |
DisclosureSEC source: 0001179110-16-019504 · edgar.xml · nonDerivative · entry 1 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,933 Read SEC document |
| July 01, 2015 Filed Jul 2, 2015 21:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,431 | $49.08 | $119,313.48 |
DisclosureSEC source: 0001179110-15-010823 · edgar.xml · nonDerivative · entry 2 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,251 Read SEC document |
| July 01, 2015 Filed Jul 2, 2015 21:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 6,076 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-010823 · edgar.xml · nonDerivative · entry 1 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,682 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| June 03, 2015 Filed Jun 5, 2015 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 5,300 | $0.00 Strike: $26.70 | $0.00 |
DisclosureSEC source: 0001179110-15-009279 · edgar.xml · derivative · entry 9 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 5,300 shares Expires 2018-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 03, 2015 Filed Jun 5, 2015 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 5,200 | $0.00 Strike: $25.25 | $0.00 |
DisclosureSEC source: 0001179110-15-009279 · edgar.xml · derivative · entry 8 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 5,200 shares Expires 2017-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 03, 2015 Filed Jun 5, 2015 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 10,500 | $49.00 | $514,500.00 |
DisclosureSEC source: 0001179110-15-009279 · edgar.xml · nonDerivative · entry 3 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,606 Read SEC document |
| June 03, 2015 Filed Jun 5, 2015 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 5,300 | $26.70 | $141,495.69 |
DisclosureSEC source: 0001179110-15-009279 · edgar.xml · nonDerivative · entry 2 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2015 Filed Jun 5, 2015 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 5,200 | $25.25 | $131,279.72 |
DisclosureSEC source: 0001179110-15-009279 · edgar.xml · nonDerivative · entry 1 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2015 Filed Mar 3, 2015 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 652 | $47.48 | $30,957.61 |
DisclosureSEC source: 0001179110-15-004029 · edgar.xml · nonDerivative · entry 3 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,606 Read SEC document |
| February 27, 2015 Filed Mar 3, 2015 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,116 | $47.61 | $53,132.76 |
DisclosureSEC source: 0001179110-15-004029 · edgar.xml · nonDerivative · entry 2 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,258 Read SEC document |
| February 27, 2015 Filed Mar 3, 2015 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 4,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-004029 · edgar.xml · nonDerivative · entry 1 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,374 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 20, 2015 Filed Feb 24, 2015 22:40 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 146,551 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003326 · edgar.xml · derivative · entry 1 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,551 Underlying: Common shares · 146,551 shares Expires 2025-02-19 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 48,851 on 2/20/16, 48,850 on 2/20/17, and 48,850 on 2/20/18. Read SEC document |
| February 17, 2015 Filed Feb 18, 2015 23:45 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 621 | $46.41 | $28,821.23 |
DisclosureSEC source: 0001179110-15-002848 · edgar.xml · nonDerivative · entry 4 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,912 Read SEC document |
| February 17, 2015 Filed Feb 18, 2015 23:45 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 283 | $46.09 | $13,043.47 |
DisclosureSEC source: 0001179110-15-002848 · edgar.xml · nonDerivative · entry 3 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,533 Read SEC document |
| February 15, 2015 Filed Feb 18, 2015 23:45 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,001 | $46.09 | $46,136.09 |
DisclosureSEC source: 0001179110-15-002848 · edgar.xml · nonDerivative · entry 2 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,816 Read SEC document |
| February 06, 2015 Filed Feb 18, 2015 23:45 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 2,966 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-002848 · edgar.xml · nonDerivative · entry 6 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 2,966 F2 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his daughter. Read SEC document |
| February 06, 2015 Filed Feb 18, 2015 23:45 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 2,966 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-002848 · edgar.xml · nonDerivative · entry 1 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,817 Read SEC document |
| November 28, 2014 Filed Dec 19, 2014 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 2,966 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-018570 · edgar.xml · nonDerivative · entry 4 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 2,966 F3 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his son. Read SEC document |
| November 28, 2014 Filed Dec 19, 2014 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 2,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-018570 · edgar.xml · nonDerivative · entry 3 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 2,967 F2 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his daughter. Read SEC document |
| November 28, 2014 Filed Dec 19, 2014 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 5,933 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-018570 · edgar.xml · nonDerivative · entry 1 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,783 Read SEC document |
| July 01, 2014 Filed Jul 2, 2014 21:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,840 | $40.90 | $75,256.00 |
DisclosureSEC source: 0001179110-14-011330 · edgar.xml · nonDerivative · entry 2 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,716 Read SEC document |
| July 01, 2014 Filed Jul 2, 2014 21:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 6,077 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-011330 · edgar.xml · nonDerivative · entry 1 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,556 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 21, 2014 Filed Feb 25, 2014 22:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 81,940 | $0.00 Strike: $39.12 | $0.00 |
DisclosureSEC source: 0001179110-14-003629 · edgar.xml · derivative · entry 1 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,940 Underlying: Common shares · 81,940 shares Expires 2024-02-20 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,314 on 2/21/2015, 27,313 on 2/21/2016, and 27,313 on 2/21/2017. Read SEC document |
| February 18, 2014 Filed Feb 19, 2014 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 489 | $38.97 | $19,053.89 |
DisclosureSEC source: 0001179110-14-003076 · edgar.xml · nonDerivative · entry 3 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,479 Read SEC document |
| February 18, 2014 Filed Feb 19, 2014 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 325 | $38.81 | $12,613.25 |
DisclosureSEC source: 0001179110-14-003076 · edgar.xml · nonDerivative · entry 2 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,968 Read SEC document |
| February 17, 2014 Filed Feb 19, 2014 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 608 | $38.81 | $23,596.48 |
DisclosureSEC source: 0001179110-14-003076 · edgar.xml · nonDerivative · entry 1 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,293 Read SEC document |
| December 06, 2013 Filed Dec 10, 2013 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 5,855 | $0.00 Strike: $25.07 | $0.00 |
DisclosureSEC source: 0001179110-13-017684 · edgar.xml · derivative · entry 4 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 5,855 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 06, 2013 Filed Dec 10, 2013 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,855 | $37.46 | $219,299.03 |
DisclosureSEC source: 0001179110-13-017684 · edgar.xml · nonDerivative · entry 2 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,901 Read SEC document |
| December 06, 2013 Filed Dec 10, 2013 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 5,855 | $25.07 | $146,803.59 |
DisclosureSEC source: 0001179110-13-017684 · edgar.xml · nonDerivative · entry 1 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2013 Filed Jul 3, 2013 21:46 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 119,700 | $0.00 Strike: $35.20 | $0.00 |
DisclosureSEC source: 0001179110-13-011553 · edgar.xml · derivative · entry 1 Pavee Jean-Yves · CIK 0001580217 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,700 Underlying: Common shares · 119,700 shares Expires 2023-06-30 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 39,900 on 7/1/2014, 39,900 on 7/1/2015, and 39,900 on 7/1/2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.